Drug Profile


Alternative Names: NSC 349438

Latest Information Update: 06 Sep 2011

Price : $50

At a glance

  • Originator National Cancer Institute (USA)
  • Class Antineoplastics; Furans; Small molecules; Terpenes
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatocellular carcinoma; Non-small cell lung cancer

Most Recent Events

  • 06 Sep 2011 Discontinued - Phase-I for Non-small cell lung cancer in USA (IV)
  • 06 Sep 2011 Discontinued - Phase-II for Hepatocellular carcinoma in USA (IV)
  • 18 Sep 2001 A phase II study in hepatocellular carcinoma patients has been added to the Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top